Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.94 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
• Cliffwater Private Credit Fund Sees 16% Redemption Requests - Bloomberg
• Victoria’s Secret shares slump 16% on weak Q3 operating income outlook